Stocktoria

EXICURE, INC. XCUR

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2018-05-09 · LEI

EXICURE, INC. financials (annual)

Revenue
$1.0M $9.7M $118000 $1.3M $16.6M -$483000 $28.8M $0 $500000 $0 2016201720182019202020212022202320242025
Net income
-$16.9M -$11.0M -$22.4M -$26.3M -$24.7M -$64.1M -$2.6M -$16.9M -$9.7M -$4.9M 2016201720182019202020212022202320242025
Free cash flow
-$5.4M -$20.7M -$19.6M $235000 -$42.4M -$35.8M -$35.7M -$10.4M -$2.9M -$8.6M 2016201720182019202020212022202320242025

Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$0$500,000$0$28.8M-$483,000$16.6M$1.3M$118,000$9.7M$1.0M
R&D expense$3.3M$0$1.4M$19.8M$49.0M$32.1M$19.3M$14.1M$13.1M$13.7M
Operating income-$4.2M-$12.2M-$15.0M-$1.8M-$62.5M-$25.4M-$26.6M-$21.8M-$10.4M-$16.2M
Interest expense$0$595,000$1.7M$573,000$786,000$672,000$795,000$724,000
Income tax-$634,000$8,000$0$209,000$0$0$0$0$0$0
Net income-$4.9M-$9.7M-$16.9M-$2.6M-$64.1M-$24.7M-$26.3M-$22.4M-$11.0M-$16.9M
EPS (diluted)$-0.79$-4.75$-10.55$-0.56$-21.70$-0.28
Operating cash flow-$8.6M-$2.9M-$10.4M-$35.7M-$34.8M-$39.3M$1.3M-$19.5M-$19.8M-$5.0M
Free cash flow-$8.6M-$2.9M-$10.4M-$35.7M-$35.8M-$42.4M$235,000-$19.6M-$20.7M-$5.4M
Cash & equivalents$12.5M$816,000$8.6M$34.6M$33.3M$48.5M$26.3M$25.8M$19.6M
Total assets$14.0M$15.1M$11.6M$23.3M$64.9M$100.4M$115.3M$28.8M$29.0M$20.6M
Total liabilities$10.1M$8.3M$8.5M$8.4M$53.6M$38.9M$34.5M$7.8M$9.0M$18.1M
Shareholders' equity$3.9M$6.8M$3.0M$14.9M$11.2M$61.5M$80.7M$21.0M$20.0M$2.4M

Growth · year-over-year

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue growth-100.0%-100.0%-102.9%+1181.9%+998.3%-98.8%+838.1%
Free cash flow growth-18160.0%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.